Overview of the 2023 GOLD Guidelines for COPD

Target Audience
The educational design of this activity addresses the needs of primary care providers (PCPs), including physicians, nurse practitioners, and physician assistants who manage patients with chronic obstructive pulmonary disease (COPD).

Program Overview
During the first activity of the series, expert faculty will present and discuss key updates to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Report for Prevention, Diagnosis, and Management of COPD. These include changes to the definition of COPD, initial assessment of symptoms and severity, evidence supporting reduction in mortality with currently available therapies, and the objective assessment of acute exacerbations.

Educational Objectives
After completing this activity, the participant should be better able to:

Discuss relevant updates to recent GOLD guidelines on COPD management, including practical implications for daily clinical decision-making
Describe recently published clinical trial data related to triple combination therapy for patients with COPD
Tailor maintenance treatment regimens for COPD to reflect symptom severity, exacerbation risk, comorbidities, and patient needs/preferences
Faculty
Fernando J. Martinez, MD, MS
Chief, Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global and Integritas Communications. Global is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 100% on the posttest, and complete the program evaluation.

Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosures of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Fernando J. Martinez, MD, MS: Consulting Fee: AbbVie Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Chiesi USA, CSL Behring, DevPro Biopharma LLC, GlaxoSmithKline plc, F. Hoffmann-LaRoche Ltd, Lung Therapeutics, IQVIA, Novartis AG, Polarean, Inc., Pulmatrix, Inc., Pulmonx, Raziel Therapeutics, Sanofi/Regeneron, Shinogi Inc, Teva Pharmaceutical Industries Ltd., Theravance Biopharma, Viatris Inc., twoXAR, Inc., United Therapeutics Corporation, Veracyte, Inc.; Contracted Research: Afferent/Merck, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Nitto, Respivant, Roche, Sanofi/Regeneron; Other: DSMB and Event Adjudication: Boehringer Ingelheim, GlaxoSmithKline, Medtronic

The following planners and managers have no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Lauren Sinclair, Celeste Collazo, MD, Elizabeth Manheim, PhD, Jim Kappler, PhD

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.